Back to results
US 2009/0023753 A1Published application
1,3-Thiazole-5-Carboxamides Useful as Cancer Chemotherapeutic Agents
AssigneeBayer HealthCare LLC
InventorsChih-Yuan Chuang, Philip Wickens, Zhengiu Hong, Catherine Brennan, Julie A. Dixon, Harold C.E. Kluender, Charles Kreiman, Ellalahewage Kumarasinghe
Life of this patent
Estimating the term…
Abstract
This invention relates to novel 1,3-thiazole-5-carboxamide compounds, pharmaceutical compositions containing such compounds, and the use of those compounds or compositions as cancer chemotherapeutic agents.
Claims12
A compound of formula (I)
- wherein
- Ar is selected from the group consisting of
- X is CH or N;
- R1 is selected from the group consisting of
- H,
- halogen,
- wherein
- R1-2 is selected from the group consisting of
- H,
- (C1-C4)alkyl,
- wherein said (C1-C4)alkyl can be substituted with 0, 1, or 2 groups independently selected from hydroxy,
- (C1-C4)alkylamino,
- (C1-C4)acyloxy,
- (C1-C4)alkoxy, and
- (C2-C4)alkoxy substituted with 0, 1 or 2 (C1-C4)alkoxy groups,
- 5- or 6-membered heteroaryl,
- and
- phenyl substituted with 0, 1, or 2 groups independently selected from the group consisting of (C1-C4)alkyl, halo, nitro, (C1-C4)alkoxy and cyano,
- and
- wherein said (C1-C4)alkyl is independently optionally substituted with F up to the perfluoro level;
- R1-3 is H or (C1-C4)alkyl;
- R1-4, R1-5 and R1-6 are selected from the group consisting of
- H,
- indan-5-yl,
- phenyl substituted with 0, 1, or 2 groups independently selected from the group consisting of (C1-C4)alkyl, halo, nitro, (C1-C4)alkoxy and cyano,
- 5- or 6-membered heteroaryl substituted with 0, 1 or 2 groups selected from the group consisting of
- cyano,
- halo,
- nitro,
- (C1-C4)alkyl,
- wherein said (C1-C4)alkyl is optionally substituted with 0, 1, or 2 groups selected
- from
- (C1-C4)alkylamino,
- (C1-C4)acyloxy,
- (C1-C4)alkoxy,
- and
- (C2-C4)alkoxy substituted with up to 0, 1 or 2 (C1-C4)alkoxy groups,
- (C3-C6)cycloalkyl substituted with 0, 1 or 2 groups selected from (C1-C4)alkyl, (C1-C4)alkoxy, cyano, and halo,
- and
- (C1-C6)alkyl,
- wherein said (C1-C6)alkyl is independently substituted with 0 or 1 group selected from the group consisting of
- NH2,
- (C1-C4)alkoxy,
- (C2-C4)alkoxy independently substituted with 0, 1, 2 or 3 (C1-C4)alkoxy and OH groups,
- and
- independently optionally substituted with fluorine up to the perfluoro level,
- carboxyl,
- (C1-C4)alkoxycarbonyl
- (C1-C4)alkylamino,
- aminocarbonyl,
- (C1-C4)alkylsulfonyl,
- phenyl substituted with 0, 1, or 2 groups independently selected from the group consisting of (C1-C4)alkyl, halo, nitro, (C1-C4)alkoxy and cyano, 5- or 6-membered heteroaryl independently substituted with 0, 1, 2 or 3 groups selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy,
- cyano, halo, and nitro
- and
- heterocyclyl independently substituted with 0, 1, 2 or 3 groups selected from the group consisting of (C1-C4)alkyl, (C1-C4)alkoxy, cyano, and halo,
- and
- wherein said (C1-C6)alkyl is independently substituted with 0, 1 or 2 OH or halo groups,
- and
- wherein said (C1-C6)alkyl is independently optionally substituted with F up to the perfluoro level;
- and
- R1-3 and R1-4, R1-3 and R1-5, and R1-3 and R1-6, when attached to the same nitrogen atom, may form, together with the N atom to which they are attached, a 5- or 6-membered saturated heterocyclic ring selected from pyrrolidinyl, morpholinyl, thiomorpholinyl and piperizinyl optionally substituted on N with (C1-C4)alkyl,
- R1-7 is independently selected from the group consisting of (C1-C4)alkyl,
- wherein said (C1-C4)alkyl is substituted with 0, 1 or 2 groups selected from the group consisting of
- (C1-C4)alkylamino,
- (C1-C4)acyloxy,
- (C1-C4)alkoxy,
- and
- (C2-C4)alkoxy substituted with 0, 1 or 2
- (C1-C4)alkoxy groups;
- or a pharmaceutically acceptable salt thereof.
67 more elements
Dependencies are inferred from the claim text.